LEV102 Topical Gel in Acquired Blepharoptosis

Phase 1

Completed

Brief Summary: Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Detailed Description: This is a Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, single-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis. Subjects will receive a one-time application of randomized, double-masked IP. Approximately 30 subjects will be enrolled in this study. Eligible subjects will be randomized to 1 of the following 3 treatment groups in a 1:1:1 ratio and will receive a single dose of double-masked IP externally on the upper eyelid of both eyes (OU):

Recruitment & Eligibility

Inclusion Criteria

Subjects who meet all the following inclusion criteria will be eligible to participate in the study. Subjects must:

Be male or female subjects 25 years of age or older at the time of Screening (Visit 1)
Have complaints of aesthetically unacceptable upper eyelid position for both eyes making them desirous for elevation, or have complaints of superior visual field defects in both eyes that impact activities of daily living
Present with the following at Screening (Visit 1):

a. At least one eye that meets both of the following criteria: i. Margin Reflex Distance 1 MRD1 ≤2 mm (no visible central pupillary light reflex defaults to 0) ii. Current corrected VA, using subject's own prescription eyeglasses, if applicable, in the qualifying eye(s) of +0.3 LogMAR (Logarithm of the Minimum Angle of Resolution) or better as assessed by ETDRS b. Demonstrate upper eyelid elevation ≥0.5 mm change from baseline in MRD1 in both eyes in response to a single drop of oxymetazoline 0.1% ophthalmic solution)to each eye at Screening
Women of Childbearing Potential must agree to use an approved method of birth control from the date they sign the informed consent form (ICF) until after the last study visit (Follow-Up Visit)
Be able to give informed consent and willing to comply with all study visits and examinations

Exclusion Criteria

Have any other ocular pathology other than ptosis requiring treatment with topical prescription ophthalmic drops in either eye (e.g., glaucoma, dry eye)
Have narrow angles, glaucoma, intraocular pressure >23 mmHg or diagnosis of ocular hypertension, cup-to-disc ratio of >0.7, or history of any glaucoma eye surgery in either eye
Have any active ocular or peri-ocular infection; any history of recurrent or chronic infection or inflammation in either eye
Have a history of allergic reaction to the investigational drug or any of its components
Within 7 days of Screening (Visit 1), or anticipated use during the study, use of any systemic, intranasal, topical dermatologic, or ophthalmic α-adrenergic agonist (including brimonidine) or antagonist including nasal or ocular or oral decongestants including pseudoephedrine, oxymetazoline topical ophthalmic solution, oxymetazoline topical dermatologic cream
Subjects who are pregnant or breast-feeding

Arm && Interventions

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability])	Day 2-5	Adverse events

Secondary Outcome Measures

Name	Time	Method
Upper Eyelid Height	Day 1	Percentage of subjects with increase in Margin reflex distance 1 (MRD1) of 1 mm at Hours 2 and 6 on Day 1

Locations (3): Steve Yoelin Medical Associates
🇺🇸
Newport Beach, California, United States
Eye Research Foundation
🇺🇸
Newport Beach, California, United States
Brian Biesman, M.D
🇺🇸
Nashville, Tennessee, United States